We believe people living with Alpha-Gal Syndrome deserve better. This nationwide research initiative is collecting patient experiences to better understand diagnosis, treatment outcomes, barriers to care, and what the future of Alpha-Gal healthcare should look like.
Anonymous · Voluntary · Estimated 8–10 minutes
Alpha-Gal Syndrome now affects an estimated 450,000 or more Americans — a number growing rapidly as lone star tick populations expand into new regions. Cases have increased more than 5,000% over the past decade, and the condition is now being identified in states where it was previously unknown.
Despite growing awareness, many patients continue to experience lengthy diagnostic delays, limited access to knowledgeable providers, and few coordinated treatment pathways. The result is a fragmented system where patients often navigate their condition largely alone — relying on online communities rather than clinical guidance.
Rezonate is conducting independent research into the Alpha-Gal patient experience. We are not currently a clinic or a pharmaceutical company, and are not affiliated with any treatment provider.
We are gathering comprehensive data on patient diagnosis journeys, treatment outcomes, access barriers, and unmet needs. This research will help us understand what better care looks like.
If you are living with Alpha-Gal Syndrome, your experience is exactly what this research needs.
Select the survey that matches your situation. Both are anonymous and take approximately 8 to 10 minutes to complete.
For patients who have undergone Soliman Auricular Allergy Treatment. Covers your treatment experience, outcomes, side effects, and long-term results.
Start this survey →For patients living with Alpha-Gal Syndrome who have not yet received SAAT treatment. Covers your diagnosis journey, access barriers, and what you need.
Start this survey →Your responses are anonymous. We do not collect your name or any identifying information unless you voluntarily provide it at the end of the survey to opt into future follow-up.
We will never sell your data. Research responses are used solely for the purposes of this study and will not be shared with, sold to, or used by any third party for commercial purposes.
We will share what we find. Aggregate findings from this study will be shared openly with the Alpha-Gal patient community. You deserve to see what this research reveals.
Participation is entirely voluntary. You may stop at any time. There is no obligation and no consequence for not completing the survey.
We welcome questions, feedback, and direct outreach from patients, practitioners, and researchers.
research@rezonatemed.com